A prospective study to compare levonorgestrol intrauterine system and trans-cervical resection of endometrium for treatment of abnormal uterine bleeding

Kishorkumar V. Hol, Shraddha S. Shastri*, Shilpa S. Magar, Sameer P. Darawade

Department of Obstetrics and Gynecology, Smt. Kashibai Navale Medical College Narhe, Pune, Maharashtra, India

Received: 11 September 2019
Accepted: 15 November 2019

*Correspondence:
Dr. Shraddha S. Shastri,
E-mail: drshradds@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: This article is a study comparing the two most accepted forms of treatment for abnormal uterine bleeding - levonorgestrol intrauterine treatment and transcervical resection of endometrium, with regards to its acceptability, efficacy, adverse effects and user satisfaction. Aim of this study was to compare the acceptability, efficacy, adverse effects and user satisfaction of LNG-IUS and TCRE for treatment for AUB.

Methods: A prospective observational study conducted in SKNMC and GH. Forty-nine women with abnormal uterine bleeding after hysteroscopic evaluation were included in this study; where 17 opted for LNG-IUS; 32 opted for TCRE with bipolar electrode. 15 patients in LNG-IUS group and 28 pts in TCRE group completed follow up. Menstrual pattern, pictorial blood loss assessment chart score, adverse effects, acceptability, satisfaction and reason for discontinuation were recorded at 6 weeks, 6 months and 12 months after the procedure. Prior to LNG-IUS insertion or endometrial ablation, endometrial and cervical pathology were excluded by D and C and cervical smear, respectively. TVUS was used to exclude possible causes of menorrhagia, including myomas and endometrial polyp as well as adnexal pathology. LNG-IUS insertion was performed as an office procedure one day after cessation of menstrual bleeding with a negative urine pregnancy test.

Results: Menstrual blood loss reductions in TCRE and LNG-IUS groups were by 85.7% and 87.6% respectively after a year. Amenorrhoea was more common in TCRE group while spotting and systemic effects were more common in LNG-IUS group. Satisfaction and acceptance rates are higher in TCRE group.

Conclusions: The TCRE and LNG-IUS are equally effective in reducing bleeding in AUB patients. Acceptance and satisfaction are better with TCRE, as a modality of treatment for AUB.

Keywords: Abnormal uterine bleeding, Amenorrhea, Endometrium, Levonorgesterol intrauterine system, Transcervical resection of menorrhagia

INTRODUCTION

Women bring to their clinicians. Approximately 10-15% of women have HMB1, defined as a menstrual blood loss (MBL) of > 80 ml. It is often incapacitating and expensive to treat and can severely affect a woman’s quality of life. Many women are not happy with medical treatment due to prolonged duration and adverse effects so end up undergoing surgery. Hysterectomy was once the only surgical option for heavy menstrual bleeding and almost half of hysterectomies currently performed worldwide are carried out for this reason.2 Oestrogens cause nausea, vomiting and thrombo-embolic complications. Progestogens are preferred to oestrogens.
in the peri-menopausal women. Progestogens when taken orally cause nausea, vomiting, bloating, mastalgia, and depression. Surgical treatment such as hysterectomy and endometrial ablation techniques require hospitalization and anesthesia. The risks of surgical intervention, anaesthetic complications and surgical site infection are considerable.

Endometrial destruction techniques destroy or remove the endometrium. Introduced in the 1980s were:

- First generation techniques - direct hysteroscopic vision - roller ball ablation and trans-cervical resection
- Second generation non hysteroscopic techniques - devices are sited and activated to treat the whole endometrial cavity simultaneously without visual control.

**LNG**

Levonorgestrel intrauterine system which was initially introduced as an intrauterine contraceptive device has recently been used for the treatment of heavy menstrual bleeding. Intrauterine delivery of progestin is an effective way to administer local treatment and bypass systemic side effects. It has emerged as an alternative to the usual medical and surgical methods of treatment for AUB.

Antifibrinolytic agents reduce the bleeding by 40-50%, prostaglandin synthetase inhibitors reduce the bleeding by 20-25%, oral contraceptives reduce the bleeding by 40-50%, and LNG-IUS reduces the bleeding by 86-97%.

LNG-IUS has shown the greatest reduction in menstrual blood loss, and, hence has been proposed as an alternative to hysterectomy in perimenopausal women. LNG-IUS can reduce the menstrual blood loss by 92.9% (97.6-81.1%) and help to improve anemia.

LNG-IUS is also a very good alternative for women who have HMB and desire contraception. LNG-IUS is useful in treating HMB in obese women. LNG-IUS is safe in women who have undergone prior surgeries such as cesarean or myomectomy. LNG-IUS is beneficial in the treatment of uterine fibroid, endometriosis, adenomyosis and endometrial hyperplasia. Health related quality of life outcomes and cost effectiveness with LNG-IUS was found to be similar to hysterectomy or endometrial ablation in several developed countries.

Objective of this study was to compare the acceptability, efficacy, adverse effects and user satisfaction of LNG-IUS and TCRE for treatment for AUB.

**METHODS**

Prospective observational study conducted from October 2016 to April 2017 with a total 49 women with abnormal uterine bleeding after hysteroscopic evaluation were included in this study. Of these, 17 opted for LNG-IUS; 32 opted for TCRE with bipolar electrode. A total 15 patients in LNG-IUS group and 28 patients in TCRE group completed follow-up.

Menstrual pattern, pictorial blood loss assessment chart score, adverse effects and rates of acceptability and satisfaction, reason for discontinuation were recorded at 6 weeks, 6 months and 12 months after the procedure.

Prior to LNG-IUS insertion or endometrial ablation, endometrial pathology (endometrial carcinoma and/or endometrial atypical hyperplasia) and cervical pathology (cervical cancer and preinvasive intraepithelial lesions) were excluded by D and C and cervical smear, respectively. TVUS was used to exclude possible causes of menorrhagia, including myomas and endometrial polyp as well as adnexal pathology. Women participating in the study reported the duration of uterine bleeding in days prior to, and six months and 12 months after each intervention. LNG-IUS insertion was performed as an office procedure one day after cessation of menstrual bleeding.

All women had a negative urine pregnancy test prior to LNG-IUS insertion. The uterine cavity length was measured using uterine sounding followed by LNG-IUS insertion.

**Inclusion criteria**

- AUB unresponsive to medical treatment.
- Family completed
- No genital infection
- Malignancy ruled out by biopsy
- Ready to accept TCRE as treatment modality
- Uterine size with less than 8 weeks.

**Exclusion criteria**

- Undue due to severe medical illness
- Unacceptable for oligomenorrhoea or amenorrhoea
- Women with uterine or adnexal pathology
- Women desiring preservation of fertility
- Endometrial and cervical carcinoma.

**The LNG-IUS**

LNG-IUS consists of a 32 mm T shaped polyethylene frame with a reservoir containing 52 mg of levonorgestrel. The LNG-IUS releases 20 μg of levonorgestrel per day.

A plasma concentration of 150-200 pg/ml is achieved after a few weeks. The Figure 1 shows the structure of LNG-IUS. The plasma concentration of levonorgestrel in LNG-IUS users is 25% less than that seen when 150 μg of levonorgestrel is taken orally.

The slow release of levonorgestrel in the uterine cavity suppresses the endometrium and causes endometrial
glandular atrophy and stromal decidualization. Levonorgestrel: potent blocker of oestrogen activity on the endometrium; thickens the cervical mucus. All these actions of levonorgestrel on the endometrium and the cervix make LNG-IUS an effective contraceptive and a non-surgical minimally invasive long-term treatment option for menorrhagia.

![Structure of LNG-IUS](image)

**Figure 1: Structure of LNG-IUS.**

It is highly effective, with a typical-use first year pregnancy rate of 0.1% - similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion.

**Indication**

- Contraception during reproductive age and 4 weeks postpartum
- Hypermennorhea
- Endometrial protection during estrogen substitution.

**Contraindications**

- Ongoing pregnancy
- < 4 weeks post-partum
- Immediate post-abortion
- Cancer - cervix, uterus, breast
- Post septic abortion
- Anatomical abnormalities distorting uterine cavity
- Pelvic inflammatory disease - current or within last 3 months
- Pelvic tuberculosis
- Unexplained uterine bleeding
- Postpartum endometritis
- Acute hepatic affections and liver tumor; severe cirrhosis;
- Thromboembolic diseases; coagulation disorders or use of anticoagulant medicines;
- Severe anemia
- Immunosuppressive therapy
- Frequent sexual partner changes
- Hypersensitivity to levonorgestrel or to another component.

**Precautions**

Exclude endometrial pathology; without any uterine bleeding after six weeks of use, a pregnancy test is required; epilepsy; diabetes; ovarian cyst; uterine scars; history of ectopic pregnancy; non-steroidal anti-inflammatory drug use.

Gynaecological examination before insertion, 12 weeks after and then annually.

Target population: women of reproductive age, from 6 weeks up to one year postpartum who are actively breastfeeding at least 4 times per day. The method is WHO medical eligibility criteria (since the third edition in 2004), and the selected practice recommendations for contraceptive use (since the second edition in 2004). There is currently no medicated intra-uterine device available on the EML.

Others: LNG-20 IUS - release of 20 µg levonorgestrel/day occurs during the first year, 11 µg per day after 5 years with an average of 14 µg per day over 5 years.

Duration: LNG-releasing IUS is effective for five years.

Diagnostic: LNG-releasing IUS used for reversible contraception.

**Insertion**

LNG-IUS should be inserted during the first seven days of the cycle. Post-partum insertion can be done six weeks after normal delivery and twelve weeks after caesarean section.

The levonorgestrel-releasing intrauterine system, LNG-20 IUS is included in the WHO medical eligibility criteria for contraceptive use, Fourth edition, 2009, the Selected practice recommendations for contraceptive use, second edition 2004 and the family planning global handbook for providers, 2011 update.

**TCRE**

After gradual dilatation of the uterine cervix (Hegar size up to 10.5), a 26F operative hysteroscope was inserted (Storz company, Tuttlingen, Germany). The Figure 2
shows the resectoscope and the system used for TCRE. The uterine cavity was distended using isotonic solution.

![Figure 2: Resectoscope used for TCRE.](image)

The internal ostia were identified and corresponding endometrium was resected with bipolar resectoscope using current settings of 80, followed by successive resection of endometrium of the fundus and the anterior and posterior uterine wall. Fluid balance was checked throughout the procedure.

It was performed under spinal anaesthesia.

**Statistical analysis**

Following were recorded at 3-month intervals for a period of 12 months:

- Procedure-related complications
- PBAC score
- Haemoglobin levels
- Adverse effects, rates of acceptability and satisfaction.

**RESULTS**

The Table 1 shows the mean age and mean parity in both groups. The mean parity in the TCRE group was 3.2.

The Table 2 shows the etiological distribution in both the groups. Leiomyoma (Fibroids) was the commonest cause of AUB among our patients common in both the groups followed by Ovulatory dysfunction.

<table>
<thead>
<tr>
<th>Patient variable</th>
<th>LNG-IUS (N = 17)</th>
<th>TCRE (N = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>38.2</td>
<td>40.8</td>
</tr>
<tr>
<td>Mean parity</td>
<td>1.8</td>
<td>3.2</td>
</tr>
</tbody>
</table>

**Table 1: Age and parity distribution.**

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Ovulatory dysfunction</th>
<th>Fibroid</th>
<th>Adenomyosis</th>
<th>Endometrial hyperplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNG-IUS</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>TCRE</td>
<td>9</td>
<td>10</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Percentage</td>
<td>29 %</td>
<td>31 %</td>
<td>22 %</td>
<td>18 %</td>
</tr>
</tbody>
</table>

**Table 2: Etiology of AUB.**

**Table 3: Results at 6 weeks.**

<table>
<thead>
<tr>
<th>Menstrual pattern (6 weeks)</th>
<th>LNG-IUS</th>
<th>TCRE</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular cycles</td>
<td>5</td>
<td>1</td>
<td>14 %</td>
</tr>
<tr>
<td>Spotting</td>
<td>1</td>
<td>1</td>
<td>5 %</td>
</tr>
<tr>
<td>Infrequent cycles + scanty menses</td>
<td>6</td>
<td>1</td>
<td>16 %</td>
</tr>
<tr>
<td>Amenorrhoea</td>
<td>1</td>
<td>25</td>
<td>60 %</td>
</tr>
<tr>
<td>HMB</td>
<td>2</td>
<td>0</td>
<td>5 %</td>
</tr>
</tbody>
</table>

**Table 4: Results at 6 months.**

<table>
<thead>
<tr>
<th>Menstrual pattern (6 weeks)</th>
<th>LNG-IUS</th>
<th>TCRE</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular cycles</td>
<td>4</td>
<td>1</td>
<td>11 %</td>
</tr>
<tr>
<td>Spotting</td>
<td>1</td>
<td>0</td>
<td>3 %</td>
</tr>
<tr>
<td>Infrequent cycles + scanty menses</td>
<td>3</td>
<td>0</td>
<td>7 %</td>
</tr>
<tr>
<td>Amenorrhoea</td>
<td>7</td>
<td>27</td>
<td>79 %</td>
</tr>
<tr>
<td>HMB</td>
<td>0</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Expelled</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 5: Results at 12 months.

<table>
<thead>
<tr>
<th>Menstrual pattern (12 months)</th>
<th>LNG-IUS</th>
<th>TCRE</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular cycles</td>
<td>2</td>
<td>1</td>
<td>7%</td>
</tr>
<tr>
<td>Spotting</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Infrequent cycles + scanty menses</td>
<td>1</td>
<td>0</td>
<td>3%</td>
</tr>
<tr>
<td>Amenorrhoea</td>
<td>12</td>
<td>27</td>
<td>90%</td>
</tr>
<tr>
<td>HMB</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Removed</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 6: Adverse effects.

<table>
<thead>
<tr>
<th>Duration of bleeding (days)</th>
<th>LNG-IUS</th>
<th>TCRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to intervention</td>
<td>6.8</td>
<td>7.2</td>
</tr>
<tr>
<td>Post 6 months</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Post 12 months</td>
<td>2.2</td>
<td>3.0</td>
</tr>
<tr>
<td>Reduction at 6 months</td>
<td>4.1</td>
<td>4.6</td>
</tr>
<tr>
<td>Reduction at 12 months</td>
<td>4.6</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Table 7: Subsequent treatment after failure.

<table>
<thead>
<tr>
<th>Treatment options</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hysterecotemy</td>
<td>2</td>
<td>5%</td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>TCRE → LNG-IUS</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>LNG-IUS → TCRE</td>
<td>2</td>
<td>5%</td>
</tr>
</tbody>
</table>

Table 8: Satisfaction and acceptability.

<table>
<thead>
<tr>
<th></th>
<th>LNG-IUS</th>
<th>TCRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in menstrual blood loss</td>
<td>85.7%</td>
<td>87.6%</td>
</tr>
<tr>
<td>Satisfaction and acceptance rates</td>
<td>83.2%</td>
<td>88.4%</td>
</tr>
</tbody>
</table>

Table 9: Efficacy in terms of duration of bleeding.

<table>
<thead>
<tr>
<th>Duration of bleeding (days)</th>
<th>LNG-IUS</th>
<th>TCRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to intervention</td>
<td>6.8</td>
<td>7.2</td>
</tr>
<tr>
<td>Post 6 months</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Post 12 months</td>
<td>2.2</td>
<td>3.0</td>
</tr>
<tr>
<td>Reduction at 6 months</td>
<td>4.1</td>
<td>4.6</td>
</tr>
<tr>
<td>Reduction at 12 months</td>
<td>4.6</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Table 3, 4, 5 show the results at the end of 6 weeks, 6 months and 12 months. In the TCRE group amenorrhoea was seen at 6 weeks itself and by the end of 12 months 90% of patients in the TCRE group had amenorrhoea. The table no.6 shows the adverse effects in both the groups. The duration of bleeding was reduced to 4.6 days in the LNG-IUS group and 4.2 days in the TCRE group. The Table 7 shows that 5% of patients subsequently required hysterectomy and 5% of patients treated with LNG-IUS subsequently required TCRE. After a year their reductions of 85.7% and 87.6% in menstrual blood loss in TCRE and LNG-IUS groups, respectively as shown in Table 8.

Amenorrhoea was more common in TCRE group while spotting and systemic effects were more common in LNG-IUS group.

Satisfaction and acceptance rates higher in TCRE group as shown in Table 9.

Advantages of LNG-IUS over TCRE

- It can be performed as an office procedure
- LNG-IUS insertion is non-operative and hence virtually devoid of operative complications, such as excessive trauma and bleeding
• There is no need for anaesthesia, cervical dilatation, antibiotics
• Does not preclude future fertility
• Cost-effective.

DISCUSSION

Heavy menstrual bleeding has since long been a major health problem affecting the quality of life of women all over the world.

Hysterectomy was once the only surgical option for heavy menstrual bleeding, and almost half of the hysterectomies currently performed worldwide are carried out for this reason, but it is a major surgical intervention associated with surgical risks and substantial costs. Endometrial destruction techniques, which aim to destroy or remove the endometrial tissue, include roller-ball ablation and trans-cervical resection under direct hysteroscopic vision and second generation non-hysteroscopic techniques. LNG-IUS provides a nonsurgical alternative, which is reversible and spares fertility.

The results of this study demonstrate that both LNG-IUS and TCRE clearly reduce menstrual blood loss. Responses to treatment at the end of 1 year follow up showed no significant difference between the two groups (85.7% for LNG-IUS and 87.6% for TCRE), but the rate of amenorrhoea in the TCRE group was higher (P < 0.0001). These results are similar to study by Ghazizadeh et al. In the study by Gupta et al, 97% and 94% reductions were observed in menstrual blood loss in the LNG-IUS and TCRE groups respectively. However, Crosignani et al and Istré and Trolle reported a significantly higher reduction in menstrual blood loss with TCRE than with LNG-IUS insertion. In our study, amenorrhoea was more common in the TCRE group than in LNG-IUS at 12 months posttreatment (84.3% versus 70.5% respectively). In Hidalgo et al, 44% of the women who had LNG-IUS inserted reported amenorrhoea at the 6th month of use. This rate-maintained stability in 50% of these women after 12 and 24 months of use and spotting was present in 25% of the users at 6 months, decreasing to 11% at 24 months. This rate-maintained stability at 50% after 12 and 24 months of use.

CONCLUSION

Though the patient satisfaction was almost the same in both the groups, the advantage of LNG-IUS is it is less invasive.

ACKNOWLEDGMENTS

Authors would like to acknowledge Dr. G. S. Shekhawat, Professor and Head of Department, Obstetrics and Gynaecology, Smt. Kashibai Navale Medical College and General hospital, Pune and the entire facility of Department of Obstetrics and Gynecology at SKNMCH and GH for their kind support and cooperation.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

11. Lethaby AE, Cooke I, Rees M. Progestogen or progestogen-releasing intrauterine systems for heavy


